Xeris Biopharma Holdings, Inc.
XERS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $74 | $72 | $60 | $60 |
| % Growth | 4% | 19% | 0% | – |
| Cost of Goods Sold | $11 | $15 | $9 | $9 |
| Gross Profit | $63 | $57 | $51 | $51 |
| % Margin | 85.2% | 79.6% | 85.5% | 84.2% |
| R&D Expenses | $7 | $8 | $8 | $6 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $46 | $44 | $44 | $40 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $3 | $0 | $3 | $3 |
| Operating Expenses | $57 | $52 | $54 | $49 |
| Operating Income | $7 | $4 | -$3 | $2 |
| % Margin | 9% | 6.3% | -5.1% | 2.8% |
| Other Income/Exp. Net | -$6 | -$6 | -$6 | -$7 |
| Pre-Tax Income | $1 | -$2 | -$9 | -$5 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $1 | -$2 | -$9 | -$5 |
| % Margin | 0.8% | -2.7% | -15.3% | -8.5% |
| EPS | 0 | -0.012 | -0.061 | -0.034 |
| % Growth | 100% | 80% | -76.4% | – |
| EPS Diluted | 0 | -0.012 | -0.061 | -0.034 |
| Weighted Avg Shares Out | 178 | 156 | 152 | 149 |
| Weighted Avg Shares Out Dil | 178 | 156 | 152 | 149 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $7 | $7 | $7 | $8 |
| Depreciation & Amortization | $3 | $3 | $3 | $3 |
| EBITDA | $11 | $9 | $1 | $6 |
| % Margin | 14.9% | 12% | 2% | 9.5% |